19 May 2013
Keywords: Trobalt, Epilepsy, Lovaza, Abbott
Article | 31 March 2011
Following a positive advisory panel earlier this year, the European Commission has granted marketing authorization for Trobalt (retigabine) as an ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
31 March 2011
17 May 2013
© 2013 thepharmaletter.com